logo
Plus   Neg
Share
Email

Pfizer Receives Breakthrough Therapy Designation For PF-04965842 - Quick Facts

Pfizer Inc. (PFE) announced its once-daily oral Janus kinase 1 (JAK1) inhibitor PF-04965842 received Breakthrough Therapy designation from the U.S. FDA for the treatment of patients with moderate-to-severe atopic dermatitis. The Phase 3 program for PF-04965842 initiated in December.

PF-04965842 is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. Inhibition of JAK1 is thought to modulate multiple cytokines involved in pathophysiology of atopic dermatitis including interleukin (IL)-4, IL-13, IL-31 and interferon gamma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing giant Uber Technologies has shut down a customer support office in downtown Los Angeles without providing advance notice to its staff and also laid off about 80 employees, the Los Angeles Times reported on Tuesday. Uber employees were informed their jobs would be shifted to a customer support office in Manila in order to support the business as it grows, the report said. The NextGen Consortium announced the launch of reusable cup pilots in local cafes in the City of San Francisco and City of Palo Alto, California. The local cafes have joined the Consortium's efforts to advance reusable, recyclable and/or compostable cup solutions in select pilots. NextGen Consortium is a multi-year consortium that addresses single-use food packaging waste globally. DISH Network Corp. (DISH) Wednesday reported a profit for the fourth-quarter that increased about 15 percent from last year, but quarterly revenue decreased 2 percent. Both earnings per share and revenue top analysts' estimates. Net Pay-TV subscribers for the quarter decreased by about 194,000 from the prior quarter.
Follow RTT
>